Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

15.48 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
From Takeda Pharmaceutical Company Limited
Via Business Wire
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting analyst confidence and price targets. 
Via Benzinga
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
From HUTCHMED (China) Limited
Via GlobeNewswire
Preview: Takeda Pharmaceutical's Earnings
 
Via Benzinga
Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas
From Takeda Pharmaceutical Company Limited
Via Business Wire
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
Takeda inks a licensing deal with Keros for elritercept, a late-stage anemia drug, and plans a Phase 3 trial in myelodysplastic syndromes. 
Via Benzinga
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
From Takeda Pharmaceutical Company Limited
Via Business Wire
HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
From HUTCHMED (China) Limited
Via GlobeNewswire
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients
AC Immune reports interim results from Phase 2 trial of ACI-7104.056 active immunotherapy for early Parkinson's disease. 
Via Benzinga
Urgency, Debate Mark COP29 As Leaders Push For Carbon Market Rules, Worry About Trump
Global leaders gather at COP29 to address climate change, carbon market mechanisms, and climate finance. Urgency and controversy at a fossil fuel reliant host country, but focus on establishing rules... 
Via Benzinga
Topics Climate Change
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
— US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer — 
From HUTCHMED (China) Limited
Via GlobeNewswire
Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem
From Takeda Pharmaceutical Company Limited
Via Business Wire
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
HC Wainwright has initiated coverage on Alumis, highlighting the biopharmaceutical company's lead drug candidate, ESK-001. The analyst notes ESK-001's superior clinical data compared to Bristol Myers... 
Via Benzinga
Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization
Johnson & Johnson has discontinued its Phase 2 study of mosnodenvir, an investigational antiviral candidate for dengue prevention, as part of a strategic shift in its R&D portfolio. Final efficacy data... 
Via Benzinga
Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
From Takeda Pharmaceutical Company Limited
Via Business Wire
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
From HUTCHMED (China) Limited
Via GlobeNewswire
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
Wave Life Sciences has received recent Wall Street price targets forecasting big upside. The company has a potentially "industry-leading" treatment. 
Via MarketBeat
Topics Economy
Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
From Takeda Pharmaceutical Company Limited
Via Business Wire
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Phase 2 data in rare blood cancer and a multi-billion dollar potential. 
Via Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant... 
Via Benzinga
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally. 
Via Benzinga
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous parathyroid hormone exposure and is set to launch in the U.S. with patient... 
Via Benzinga
New Study Reveals How Classical Music Could Revolutionize Depression Care
In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of... 
Via PressReach
Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?
Takeda Pharmaceutical stock rises following European Commission approval of Adzynma for treating ADAMTS13 deficiency in cTTP patients. Adzynma is the first enzyme replacement therapy in the EU for this... 
Via Benzinga
Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q1 2024
Takeda Pharmaceutical just reported results for the first quarter of 2024. 
Via InvestorPlace
Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline
From Takeda Pharmaceutical Company Limited
Via Business Wire
3 Biotech Stocks to Buy on the Dip: July 2024
Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.